Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2193-651X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review ; day:21 ; month:4 ; year:2021 ; pages:1-18
Pain and therapy ; (21.4.2021), 1-18

Urheber
Blumenfeld, Andrew M.
Frishberg, Benjamin M.
Schim, Jack D.
Iannone, Ashley
Schneider, Gary
Yedigarova, Larisa
Manack Adams, Aubrey
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s40122-021-00264-x
URN
urn:nbn:de:101:1-2021060718512869686541
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:49 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Blumenfeld, Andrew M.
  • Frishberg, Benjamin M.
  • Schim, Jack D.
  • Iannone, Ashley
  • Schneider, Gary
  • Yedigarova, Larisa
  • Manack Adams, Aubrey
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs

CGRP and migraine: neurogenic inflammation revisited

CGRP and migraine: neurogenic inflammation revisited

Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis

Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy

Verbundene Objekte